Depemokimab significantly reduces asthma exacerbations, benefiting patients regardless of their baseline asthma control levels. A biologics license application for depemokimab is currently being ...

GSK, which also has phase 3 programmes running for depemokimab in EGPA and HES, has previously put a target peak sales figure of £3 billion ($3.9 billion) a year on the drug.

GSK's long-acting drug antibody for severe asthma, depemokimab, cut the rate of attacks by 54% in phase 3 trials presented at ERS.

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

Find the latest GlaxoSmithKline Pharmaceuticals Limited (GLAXO.NS) stock quote, history, news and other vital information to help you with your stock trading and investing.